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ABSTRACT 
English Version 
Tittle: Factors associated with nonachievement of LDL-C target  among patients with Type 2 
Diabetes Mellitus. 
 
Introduction: Dyslipidaemia is a risk factor for cardiovascular disease and Type 2 Diabetes 
Mellitus is a cardiovascular risk equivalent. Low density lipoprotein cholesterol (LDL-C) is 
the primary target in the management of dyslipidaemia and achievement of LDL-C target 
according to National Cholesterol Education Programme (NCEP-ATP III) is crucial.  
Statins are potents drug to reduce cholesterol especially the LDL-C,   however the 
effectiveness is limited  by the poor adherence.  
 
Objectives: To determine proportion of patients achieve LDL-C target and factors associated 
with nonachievers and the adherence to statin therapy  among patients with T2DM. 
 
Methodology: A cross sectional study involving 234 patients aged 18 years old and above 
who had comorbid Type 2 Diabetes Mellitus and Dyslipidaemia. Systematic Random 
Sampling with replacement method was applied to select participants who attended KRK, 
HUSM from January 2013 to May 2013. Both self-administered and interviewered 
administered questionnaires were  used to obtain the socio demographic characteristics, 
clinical characteristics and compliance questionnaire. The data was analysed for descriptive 
statistic and multiple logistic regression.  
xii 
 
Result: The percentage of LDL-C target achievement was  37.6%. The percentage of patients 
adhered  to statin therapy was 98.3% and 20.5% of patients  adhered fully. There was no 
significant relation between LDL-C achievement and adherence. Sociodemographic 
data(such as age, marital status, gender, education level and  household income) and clinical 
data (such as smoking status, number of prescribed medications, BMI, SBP,  duration on 
statin therapy and type of statin taken) were not associated with achievement of LDL-C 
target. HbA1c  is the only significant factor that associated with LDL-C target achievement. 
 
Conclusion: Achievement of LDL-C target among T2DM patients attended KRK,HUSM was 
still low. Majority patients were adhered to statin therapy however the relation between 
adherence and LDL-C achievement was not significant. HbA1c was the only significant 
factor associated  to nonachievement of LDL-C target. Patients with poorly control glycaemic 
control should more holistically manage including achieving their LDL-C target. 
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Malay Version 
 
Tajuk: Faktor-faktor yang mempengaruhi bukan pencapai dan kepatuhan terhadap ubat 
kolesterol jenis statin  di kalangan pesakit Kencing Manis Jenis 2. 
 
 Pengenalan: Dyslipidaemia adalah faktor risiko bagi penyakit kardiovaskular dan penyakit 
Kencing Manis jenis 2 adalah risiko kardiovaskular yang setara. Kolesterol lipoprotein 
ketumpatan rendah adalah sasaran utama dalam pengurusan dyslipidaemia dan 
pencapaiannya mengikut National Cholesterol Education Programme (NCEP-ATP III) 
adalah penting.  Statin adalah ubat antikolesterol yang berkesan untuk mengurangkan 
kolesterol terutamanya  kolesterol lipoprotein ketumpatan rendah. Walau bagaimanapun 
keberkesanannya adalah terhad disebabkan oleh ketidakpatuhan terhadap ubat antikolesterol. 
 
Objektif: Untuk menentukan tahap pencapaian sasaran koleterol lipoprotein ketumpatan 
rendah, faktor-faktor yang mempengaruhi bukan pencapai dan peratus kadar pematuhan 
terhadap ubat kolesterol jenis statin. 
 
Metodologi: Ini adalah kajian rentas yang melibatkan seramai 324 pesakit berumur 18 tahun 
dan ke atas yang menghidapi penyakit Kencing Manis Jenis 2. Pemilihan sampel secara 
Sistematik Rambang telah dilakukan untuk memilih peserta yang datang ke KRK, HUSM 
dari Januari 2013 hingga Mei 2013. Borang soal selidik telah digunakan untuk mendapatkan 
ciri-ciri sosio demografi, ciri-ciri klinikal dan soal selidik pematuhan terhadap ubat. Data 
yang diperolehi telah dianalisis menggunakan statistik deskriptif dan regresi logistik 
berganda. 
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 Keputusan: Peratusan pencapaian sasaran kolesterol lipoprotein  ketumpatan rendah adalah 
37.6%. Peratus pematuhan kepada ubat kolesterol jenis statin  adalah 98.3% dan 20.5% 
pesakit telah patuh sepenuhnya. Tiada hubungan yang signifikan antara tahap pencapaian 
kolesterol lipoprotein ketumpatan rendah dan pematuhan terhadap ubat kolesterol jenis statin. 
Data sosiodemografi (seperti umur, status perkahwinan, jantina, tahap pendidikan dan 
pendapatan isi rumah) dan data klinikal (seperti status merokok, jumlah ubat-ubatan diambil, 
jisim index badan, tekanan darah sistolik, tempoh menggunakan ubat kolesterol jenis statin 
dan jenis statin yang diambil) tidak mempunyai kaitan dengan tahap pencapaian sasaran 
kolesterol lipoprotein ketumpatan rendah. HbA1c merupakan satu-satunya faktor yang 
ditemui mempunyai kaitan dengan tahap pencapaian lipoprotein ketumpatan rendah.  
 
Kesimpulan: Pencapaian sasaran kolesterol lipoprotein ketumpatan rendah di kalangan 
pesakit Kencing Manis Jenis 2  di KRK, HUSM adalah masih rendah. Majoriti pesakit telah 
patuh  terhadap pengambilan ubat kolesterol jenis statin. HbA1c adalah satu-satunya faktor 
signifikasi  yang mempunyai perkaitan  dengan tahap pencapaian kolesterol lipoprotein 
ketumpatan rendah. Pesakit yang mempunyai kawalan gula yang lemah perlu dirawat secara 
holistik termasuk memastikan target LDL-C juga dicapai.
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CHAPTER 1 
 
INTRODUCTION 
 
1.1  Dyslipidaemia and Cardiovascular disease 
 
Cardiovascular disease include coronory heart disease, cerebrovascular disease and 
peripheral arterial  disease. Coronory heart disease is a spectrum of stable angina, ischaemic 
heart disease and myocardial infarction. According to Ministry of Health Malaysia, 
cardiovascular disease was the leading cause of death in 2009 for both men and women. In 
2008, World Health Organization reported that cardiovascular disease is the top leading cause 
of death in the world among countries with average and high incomes  which accounted about 
13% to 16% of death.  National Cardiovascular Disease – Acute Coronory Syndrome Registry 
(NCVD-ACS 2006-2008) reported that there is a high prevalence of established 
cardiovascular risk factor among patients with ACS which is rated at 31% to 35% in which 
patients had history of dyslipidaemia and in overall, 55.9% had abnormal cholesterol level(1).  
 
Dyslipidaemia is a major risk factor for cardiovascular disease(2). Many 
epidemiologic studies have shown that dyslipidaemia is a strong predictor of the likelihood 
that an individual will developed cardiovascular disease. High LDL and low HDL has been 
demonstrated as risk factors which are causally linked to cardiovascular disease(2). 
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 The Strong Heart Study assessed the cardiovascular disease risk factors in diabetic 
individuals. In this large cohort study, it was found that LDL cholesterol was a strong 
independent predictor of coronory heart disease and hazard ratio indicates that a 
10mg/dL(0.6mmol/l) increase in LDL choleserol levels would lead to a 12% increase in 
cardiovascular disease(3). It is crucial to manage dyslipidaemia accordingly and 
pharmacological treatment should be initiated early if indicated. To achieve the target of 
controlled blood cholesterol level is not only done through  drug therapy but also 
simultanously with the therapeutic changes of life style. A 12 years follow up study in the 
Russian Lipid Research Clinics observed a contradictory finding regarding association of risk 
of coronory heart disease and cholesterol level(4). Men with very low LDL-C had increased 
in coronory heart disease mortality and was described as a J-shaped curve. CHD death rate in 
men Russian patients with LDL-C less than 2.9mmol/l was slightly higher than patients with 
LDL-C between 2.9mmol/l to 3.4mmol/l resulting a J-shaped curve. However, they concluded 
that the J-shaped   relationship between LDL and CHD mortality was associated with lifestyle 
characteristic such as low educational achievement, high alcohol consumption, higher history 
of current smoking and lower mean BMI.  
 
1.2 Dyslipidaemia and Diabetis Mellitus 
 
Type 2 Diabetes Mellitus had more significant impact to the development  of multiple 
microvascular and macrovascular complications  including coronary heart disease.  Major 
clinical trials such as Multiple Risk Factor Intervention (MRFIT), The Prospective 
Cardiovascular Munster Study (PROCAM) and The Framingham Heart Study had shown 
relationship between Diabetes Mellitus and Coronory Heart Disease mortality(5-7).  
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National Health Morbidity Survey in 2011 found that 35.1% of adult aged 18 years old 
and above had hypercholesterolaemia and 26.6%  were previously undiagnosed with 
hypercholesterolaemia(8). 
 
Dyslipidaemia and Diabetes Mellitus are major predictors for cardiovascular disease 
as both clinical condition have an effect towards macrovascular disease and formation of 
artherogenesis (9). Individual with both clinical conditions are considered to be at a  higher 
risk in developing cardiovascular disease and treating to target is really important to prevent 
further morbidity and mortality resulting from cardiovascular events.  
 
The recognised features of LDL-C that predispose it becoming atherogenic and 
tending to promote the formation of fatty plaques in the arteries  are small dense LDL-C and 
excessive postprandial lipemia(10). Small dense LDL-C particles easily penetrate the vascular 
endothelium and get deposited in the walls of the vessels(11). The percentage of individuals 
possessing small and dense LDL-C is higher by at least  2 folds in T2DM(11). Among 
patients with established cardiovascular disease or cardiovascular risk equavalent,  
pharmacotherapy should begin with adjuvant to therapeutic lifestlye modification including 
exercise and dietery intervention. LDL –C is the primary target for therapy and is dependant 
upon an individual‗s global cardiovascular risk.  
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1.3 Low Density Lipoprotein Cholesterol 
 
Low density lipoprotein (LDL) is one of the five major groups of lipoproteins and the 
cholesterol which is bind to it is known as LDL cholesterol or is also well known as a bad 
cholesterol. The five major lipoproteins including chylomicrons, very low density lipoprotein 
(VLDL), intermediate density lipoprotein (IDL), low density lipoprotein and high density 
lipoprotein varies in the term of size from largest to smallest. These lipoproteins have a 
function for transporting lipids like cholesterol and tryglycerides within  the water based 
blood stream. LDL particles are very similar in size to the normal gaps in the endithelium. 
LDL particles can transport cholesterol into the arterial wall and be retained as arterial 
proteoglycans which attract macrophages that engulf the LDL particles and start the formation 
of plaques. These condition increased the risk of atherosclerosis. The atherogenicity of LDL 
cholesterol is well established and proven in many studies. Most of the major clinical trials 
have shown a direct relationship between level of LDL cholesterol and the risk of coronory 
heart disease either in a previously healthy population or in patients with the related diseases 
such as hypertension and diabetes mellitus. National Cholesterol Education Programme – 
Adult Treatment Plan I to III (NCEP-ATP III) has established  LDL cholesterol as a primary 
target of therapeutic interaction because LDL cholesterol plays a major role in initiating the 
development of atherosclerotic plaque. Meta analysis have shown that reducing total 
cholesterol by 1mmol/l significantly  reduces mortality due to coronory heart disease(12).  
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Justification of research 
 
This research is conducted to determine primary lipid target achievement which is low 
density lipoprotein cholesterol and the adherence to statin therapy in patients with comorbid 
Type 2 Diabetes Mellitus and Dyslipidaemia. National Cholesterol Education Programme – 
Adult Treatment Plan I to III (NCEP-ATP I -III) has established LDL cholesterol as a primary 
target of therapeutic interaction because LDL cholesterol plays a major role in initiating the 
development of atherosclerotic plaque. It is  crucial to achieve the target of LDL-C according 
to the recommended level as it prevent further risk of cardiovascular event. This study 
evaluated the current performance of LDL-C achievement in patients with Type 2 Diabetes 
Mellitus and reflected the management of dyslipidaemia of Type 2 Diabetes Mellitus. The 
adherence to lipid lowering therapy particularly statin group which was stated as the most 
potent antilipid in reducing LDL-C level is also important. Being aware of  the factors 
associated with LDL-C achievement,  can assist us in recognising  patients which have 
tendency to become non-achievers to LDL-C target. It is also important to identify underlying 
socioeconomic and lifestyle-related factors in order to begin  appropriate interventions and 
management. 
 
Our primary health care setting has a vast array of patients  charactheristic with 
demographic differences,  patients from the rural areas, semiurban area as well as urban area 
seeking treatment in the same facility. The information obtained from this study is useful for 
the health care providers to evaluate the achievement of cholesterol level and medication 
adherence in their own health care setting . 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 LDL-C target in Dyslipidaemia and Type 2 Diabetes Mellitus 
 
 In Clinical Practice Guidelines on Management of Dyslipidaemia 2011, the 
optimal primary target of LDL-C value is dependent upon the patients assessment of global 
cardiovascular risk factors(13). NCEP-ATP III recognised three risk group categories and the 
LDL-C target is dependent upon to the risks that fall into(14). The three risk groups are low 
risk(≤1 risk factor), moderate risk(>2 risk factors) and high risk category (CHD and CHD risk 
equivalents), where in their LDL-C  target are <4.1mmol/l, <3.4mmol/l and <2.6mmol/l. The 
target for patients with dyslipidaemia and Type 2 Diabetes Mellitus in accordance to NCEP-
ATP III is <2.6mmol/l and this target is similar to the American Diabetes 
Association(ADA)(15).  
 
Canadian Diabetes Association(CDA)  stated in the 2008 practice guideline that the 
LDL-C target for Type 2 Diabetes Mellitus is ≤2.0mmol/l which is much lower than NCEP-
ATP III(16). European Atherosclerotis Society/ European Society of Cardiology(EAS/ESC) 
recommended the primary LDL-C target for patients with very high risk and high risk 
as<1.8mmol/l and <2.5mmol/l(17). American College of Cardiology/ American Heart 
Association(ACC/AHA) published its latest guideline in 2013 for the treatment of blood 
cholesterol to reduce risk of Atherosclerotic Cardiovascular Disease(ASCVD) in adults;  
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raising many controversial issues(18). In the guideline, there is no target of LDL-C and 
patients will be treated according to the four statin benefit group. There will be three options 
of treatments for these group of patients which encompass high intensity statin, moderate 
intensity statin and low intensity statin. Patients with comorbid Dyslipidaemia and Type 2 
Diabetes Mellitus  will be classified under the group that needs be treated with high intensity 
statin(atovastatin 40mg to 80mg or Rosuvastatin 20mg). 
 
2.2 Statin therapy in dyslipidaemia 
 
Statins are the most effective drug class and is the treatment of choice in reducing Low 
Density Lipoprotein Cholesterol and they also have an additional effect of antiatherosclerothic 
propeties(13, 14, 17). It inhibits 3-Hydroxy-3methyl glutaryl coenzyme A  Reductase 
(HMGCoA Reductase) in the liver and limits the rate of hepatic cholesterol synthesis. It is 
used as the first line agents in Familial Hypercholesterolemia, primary prevention of 
cardiovascular disease, secondary prevention of cardiovascular disease and coronory heart 
disease equivalents(13, 19, 20). A natural compound with inhibitory effect towards HMG-
CoA Reductase was discovered in 1970s by Japanese microbiologist, Akira Endo in a 
fermentation broth of Penicillium citrinum during a search for antimicrobial agents(21). 
Lovastatin was the first statin to be developed and later followed by simvastatin in 1988, 
pravastatin in 1991, fluvastatin in 1994, atorvastatin in 1997 and resuvastatin in 2003. The 
mean reduction of LDL-C level with the maximal recommended dose of different statin 
ranges from 35% to 55%(14). 
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 Many landmark clinical  trials have shown the benefits of statins for primary and 
secondary prevention(22-26). These benefits were evident in patients with coronary heart 
disease and high or normal blood cholesterol concentrations, as well as in asymptomatic 
patients at increased risk of coronary heart disease. The instances  of studies conducted 
encompassed  Scandinavian Simvastatin Survival Study(4S) ,  Long-term Intervention with 
Pravastatin in Ischemic Disease(LIPID),  Cholesterol And Recurrent Events trial(CARE),  
West of Scotland Coronary Prevention Study(WOSCOPS) and Air Force/Texas coronary 
atherosclerosis Prevention Study (AFCAPS/TexCAPS).  
 
In 4S study, 4444 patients with angina pectoris or previous myocardial infarction and 
serum cholesterol 5.5-8.0 mmol/L on a lipid-lowering diet were randomised to double-blind 
treatment with simvastatin or placebo(23). This study showed that long-term treatment with 
simvastatin is safe and improves survival in CHD patients. Sacks et al  studied  the effect of 
pravastatin on coronary events after myocardial infarction in patients with average cholesterol 
levels demonstrated that the benefit of cholesterol-lowering therapy extends to the majority of 
patients with coronary heart disease who have average cholesterol levels(19).  
AFCAPS/TexCAPS study was conducted in year 1998 in a healthy individual with average 
serum cholesterol level  treated with Lovastatin 20-40mg ON(22). The reduction of LDL-C 
by 25% was noted and the incidence of first acute major coronory events in men and women 
had significantly reduce (183 vs 116 first event;Relative Risk[RR],0.6;95% Confidence 
Interval[CI]0.5-0.79;P<0.01)(22). 
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2.2 LDL-C Achievement and its associated factors 
 
Many studies had been investigating into the LDL-C achievement in patients with 
cardiovascular risk factors or patients with cardiovascular disease(27-29). Despite the 
effectiveness of lipid lowering agents with specific preference for statin, the results of 
attainment of LDL-C by patients  varied in each study. A multinational study examined 
patients with different risk categories found that a good percentage of patients attained their 
LDL-C which in overall was 73%(30). The researchers also found that most of the achievers 
of LDL-C goal attaintment(74%) belong to the low risk category. The predictors to the 
success rate were lipid lowering therapy, lower risk group, geographic region, male gender, 
older age, race, absence of dietary counselling, diabetes and hypertension(30).  
 
An almost identical  study was done by Al-Khateeb et al which looked into the 
attaintment of LDL-C among patients with dyslipidaemia in Malaysia(28). They also 
discovered that low risk group had achieved their cholesterol target better than the high risk 
group and lower baseline LDL-C value was also inversely related to therapeutic goal 
attainment(28). The results from the National Cholesterol Education Programme Evaluation 
Project Utilizing Novel E Technology II (NEPTUNE II) showed evidence of ethnic 
differences in achievement of cholesterol treatment goals(31). NEPTUNE II was conducted 
among a group of patients treated with statin therapy which were recorded in the patients 
personal medical database. In the study, they concluded that the low achievers in LDL-C goal 
attainment among Africans American was due to less aggressive management in this ethnic 
group and suboptimal compliance. The other predictors of the treatment success found in this 
study were gender, obesity, level of triglycerides, diabetes, high efficacy statin therapy used 
and compliance to diet therapy.  
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 The undertreatment of LDL-C was investigated in a study done by Pearson et 
al. They looked into the awareness among the physicians of the NCEP guidelines and how 
well these guideline were being implemented in their clinical practice(32). It was also called 
the Lipid Treatment Assessment Project(L-TAP) with the main objective of  looking for 
utilization of lipid lowering therapy in the primary care practitioners(32). The LDL-C 
achievement in patients with coronory heart disease were very low(18%) and researcher 
found that the physicians tended not to titrate the dose of statin or use combination therapy. 
This was an old study done in 1997 in the era in which potent statin such as atorvastatin was 
still unavailable. 
 
 An interventional study by Afonso et al evaluated the effectiveness of patient 
education programme and provider awareness and the impact toward improvement in LDL-C 
attainment(33). The study  discovered that only 35.5% of patients achieved their LDL-C 
target at baseline which later increased to 59.8% after the intervention programme and 97.3% 
of the achievers were patients with higher level of adherence to medication. The intervention 
was a single 15 minutes session individual education by a trained research assistant. The 
information provided were cholesterol content in food, a low cholesterol diet, the importance 
of medication adherence and risk associated with hyperlipidaemia. The subjects  were  
patients with higher risk for cardiovascular event such as CHD, DM, multiple risk factors that 
confer a 10-year risk for coronory artery disease more than 20% or other clinical forms of 
atherosclerotic disease(33). The LDL-C target achievers were those in older age group and 
who consumed a greater number of medications compared to the nonachievers. Patients‘ 
education is very important as it can improve their knowledge, awareness about diseases and 
built up self empowerment. 
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2.3 Medication adherence 
 
Compliance, adherence and persistance are the terms that always been used in the 
literature to describe the behaviour of medication consumption(34). Currrently, the term 
adherence has become a  preferred term because it describe the agreement of medication 
taking behaviour between patient and physician(35).  It is well known that adherence plays an 
important role in management of disease to make the treatment productive and yields  
satisfactory outcome in the end.  Many studies had demonstrated that the causes of the 
nonadherence can be due to cost of the drug, side effect of the drug, scepticism towards the 
effectiveness of the drug, improved conditions as well as consumption of too many 
prescription(36-39).  
 
Nonadherence to medications is common for patients with chronic illnesses such as 
cardiovascular disease, diabetes, hypertension and dyslipidaemia. According to the World 
Health Organisation, nonadherence with long term medication for conditions such as 
hypertension, dyslipidaemia and diabetes is a common problem that leads to compromised 
health benefits and serious economic consequences in term of wasted time, money and 
uncured disease(40).  One review article found the  nonadherence toward medication was 
41% overall, 36% for antihypertensives, 42% for antidiabetics and 49% for lipid lowering 
agents(38). Natarajan et al conducted a patient self report survey at primary care clinic to 
measure patients adherence to statin therapy using a 4 item Morisky Scale. The rate of 
nonadherence to statin therapy showed a lower rate  of nonadherence which was 37%(41).  
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Another study by Birmingham et al at different primary care setting found 
approximately about 51% patients were not adhered to statin therapy and one quater of it 
described as intentional which meant it arises from patients‘ decisions based on their health 
experiences and beliefs(42). 
 
2.3.1 Measurement of medication adherence 
 
World Health Organization 2003 described adherence as a multidimensional 
phenomenon which is determined by five set of factors including socioeconomic factor, health 
care system, condition related, therapy related, and patient related(40).  Adherence can be 
assessed through several different ways. Adherence to medication can be assessed either 
through direct methods or indirect method. The examples of direct method are direct observed 
therapy, measurement  of the level of medicine or metabolite in the blood and measurement of 
the biological marker in the blood. The examples of indirect methods are patient‘s 
questionnaire / patient‘s self report, rate of prescription refills, pill counts, assessment of the 
patient‘s clinical response, electronic medication monitors, measurement of physiologic 
markers and patients‘ diaries(43). Systematic review of an article by Vermiere et al found that 
direct method is the most accurate method to assess adherence(43).  
 
Measurement level of medicine and markers in blood are the most accurate method but 
it is invasive, unacceptable and costly. Direct Observe Therapy is also an accurate method but 
it is not practical to be applied to all kind of disease as it involved more human resources and 
need patients‘ commitment. Indirect method is more frequently used worldwide especially in 
medical research. Interview and all self reported methods are vulnarable to overestimates of 
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compliance and underestimate of noncompliance(43). Questionnaires and diaries were found 
to be moderate to highly concordance to with most of other measure of medication 
adherence(44). However, interview based self reporting less likely to be concordance with 
nonself report medication adherence(44). 
 
The most commonly used in the study are rate of prescription refills (propotion of days 
covered (PDC)/ Medication Possesion Rate(MPR ) and  4 or 8 item Morisky Medication 
Adherence Scale (MMAS)(35). Prescription refill dates such as Medication Possession 
Ratio(MPR) or Medication Refill Adherence(MRA) depends on the completeness of the 
pharmacy database and counting tablet given to patients often overestimates compliance(43). 
Electronic devices or Medication Event Monitoring System(MEMS) also provide more 
accurate method for adherence measurement. This system enables both frequency and times 
of opening the medication bootle to be measured(43). MEMS led to discovery of ‗drug 
holidays‘ or ‗white coat adherence‘ where the patient‘s adherence pattern correlate with the 
time to meet physicians. Medication Compliance Questionnaire(MCQ)  is a newly developed 
and validated tool to be used in assessing adhenrence to medication and was found useful to 
be used in patients with chronic illnesses(45).  Despites of presence of various method in 
measurement medication adherence, there is still no definite gold standard method(35). 
However, indirect method was preferable as it more convenient and easy to be adminstered.  
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2.3.2 Predictors to poor adherence to medication 
 
 Many studies have looked into factors that influenced poor adherence towards 
medications. Few major predictors that have been described by various studies include side 
effects of medication, presence of cognitive impairment, treatment of asymptomatic disease, 
missed appointments, complexity of treatment and poor provider-patients relationship(35). 
Richard et al studied the adherence pattern among patients with co-morbid hypertension and 
dyslipidaemia. The major predictors for adherence noted in this study were patients who were 
initiated with both antihypertensive and antilipid therapy, patients with previous coronory 
artery disease or congestive cardiac failure and also patients who took less medication(46).  
 
Study by Stilley et al looked into the relationship between psychological and cognitive 
function with adherence to cholesterol lowering therapy and found that estimated IQ were the 
strongest predictors of medication adherence(47) . Mood and personality did not not illustrate 
any significant relationship with medication adherence. Likewise, demographic characteristics 
such as income and education level in that study were indicated as not significantly related to 
medication adherence. 
 
However, Natarajan et al described the younger patients between 40 to 54 years old 
tend to  adhere less to statin therapy compared to patients of 65 years old and above(41). The 
study also discovered that the patient‘s belief and perceptions towards medications gave an 
impact towards the effect of the medication; if the patients believed by taking statins lower 
their risk of getting heart attacks or strokes, they will adhere better to statin  therapy.  
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2.4 LDL achievement and adherence 
         National Cholesterol Education Programme(NCEP) has established LDL-C as the 
primary target of therapeutic intervention and the target level of LDL-C will be based on 
individual cardiovascular risk. In patients with Type 2 Diabetes Mellitus, the  recent NCEP 
Adult Treatment Panel III guidelines stated that the target level is less than 2.6mmol/l.  
Afonso et al studied the achievement of LDL cholesterol level in high risk patients. 
The study evaluated the effectiveness of combined intervention targeting the patients and the 
providers(33). The interventions include educating patients regarding their cholesterol level, 
risk factors and medication adherence. It is demonstrated that these combined interventions 
were successful in improving adherence to medication and at the same time improved the 
LDL-C goal attaintment. Eventhough many studies looking into medication adherence, the 
relationship between medication adherence and achievement of LDL-C target is still 
underexamine. 
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CHAPTER 3 
 
OBJECTIVES 
 
3.1 General Objectives 
To determine the proportion of patient achieving target of low density lipoprotein cholesterol, 
the associated factors to nonachievement of LDL-C target  and adherence to statin therapy 
among patients with Type 2 Diabetes Mellitus. 
3.2 Specific objectives 
1.  To determine the proportion of low density lipoprotein cholesterol target level 
achievers and nonachievers among patients with Type 2 Diabetes Mellitus. 
2.  To determine the percentage of patients‘ adherence to statin therapy among patients 
with Type 2 Diabetes Mellitus. 
3. To determine the  associated factors to nonachievement of LDL-C target among 
patients with Type 2 Diabetes Mellitus. 
3.3 RESEARCH HYPOTHESIS 
Sociodemographic and clinical factors including nonadherence to statin therapy are associated 
with the nonachievement of LDL-C target. 
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3.4 Operational definition 
 
1. Low density lipoprotein cholesterol(LDL-C) achievement is based on the National 
Cholesterol Education Programme –Adult Treatment Panel III. This study only measured the 
general LDL-C target for patients with Type 2 Diabetes Mellitus in accordance to the 
guideline which is less than 2.6mmol/l. The achievers for LDL-C target are grouped  as 
below: 
(i) LDL-C target achievers = diabetic patients who attained LDL-C level < 2.6mmol/l 
(ii)LDL-C target nonachievers = diabetic patients who attained LDL-C level ≥2.6mmol/l 
 
2. A patient is considered to adhering to medication if he/she scored a total percentage of 
 ≥ 75%  in Medication Compliance Questionnaire. We devided the category of adherence in 
our study as below: 
i- Fully adhered: patients who attained 100% score in MCQ 
ii- Adhered: patients who attained ≥75% score in MCQ 
iii- Nonadhered: patients who attained <75% score in MCQ 
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CHAPTER 4 
METHODOLOGY 
4.1 Study design 
This  is a  cross sectional study.  
4.2 Study area 
This study was conducted in Klinik Rawatan Keluarga(KRK), Hospital Universiti 
Sains Malaysia(HUSM) which is situated in Kubang Kerian, Kelantan. HUSM also a centre 
for referral for whole state of Kelantan. Klinik Rawatan Keluarga is an outpatient clinic and is 
run by 50 staffs including the Family Medicine Lecturers, the Family Medicine Specialist in 
training, medical officers and nurses. Daily attendance in KRK ranges from 200 to 300 
patients. KRK is an integrated clinic and Diabetes Mellitus is one of the major chronic illness 
who visit KRK. 
 
4.3 Population and sample  
4.3.1 Reference population 
      Reference population was  the patients with Type 2 Diabetes Mellitus in Kelantan. 
 
4.3.2 Source population 
      Source population was the patients with Type 2 Diabetes Mellitus attending  Klinik 
Rawatan Keluarga in Hospital Universiti Sains Malaysia.   
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4.3.3 Study population 
Patients with Type 2 Diabetes Mellitus who attended  Klinik Rawatan Keluarga in 
Hospital Universiti Sains Malaysia from January 2013 to May 2013 and fulfilled the inclusion 
and exclusion criteria.  
 
4.3.4  Inclusion criteria  
1. Age 18 years old and above. 
2.  Patient  diagnosed with Type 2 Diabetes Mellitus. 
3.  Patient  diagnosed with Dyslipidaemia. 
4. Duration of undergoing statin therapy were more than 6 months. 
 
4.3.5  Exclusion Criteria  
1. Patient with psychiatric illness or mental retardation. 
2. Unable to read or write.                                                                                                                                                                                                                                                                                                                                                                        
3. Triglycerides > 4.3mmol/l 
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4.3.6  Sampling method 
Systematic random sampling in the ratio 1:2 based on patient attendance list for blood taking in 
KRK.  
 
4.3.7  Sample size calculation 
Sample size was calculated for all the objectives. However, the one that yield the biggest number 
was taken as the sample size. The probability of non-respond, drop out or missing data was 30%. 
  
Objective 1: To determine the proportion of low density lipoprotein cholesterol target level 
achievers and nonachievers among patients with Type 2 Diabetes Mellitus. 
Calculation of sample size using formula single proportion. 
n = ( z / Δ )² p ( 1 – p )  
n = minimum required sample size  
z = value of standard normal distribution = 1.96  
Δ = absolute precision = 0.07  
p = anticipated proportion of LDL-C achievers (48) 
p = 0.44 
        n= 193 
               n + 30% drop off = 251 
 The minimum sample size calculation is 193 and after considering 30% non 
respondent, the sample size is 251. 
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Objective 2: To determine the patients‘ adherence toward statin therapy among patients with 
Type 2 Diabetes Mellitus. 
Calculation of sample using formula single  proportion. 
n = ( z / Δ )² p ( 1 – p )  
n = minimum required sample size  
z = value of standard normal distribution = 1.96  
Δ = absolute precision = 0.07  
p = anticipated proportion of adherence to statin (41) 
p = 0.37 
n=180 
n+30% drop off =234 
The minimum sample size calculation is 180 and after considering 30% of the non 
respondent, the sample size is 234. 
 
Objective 3: To determine the associated factors to nonachievement of LDL-C target among 
patients with Type 2 Diabetes Mellitus. 
Categorical variables 
The sample size calculation was done using Power and Sample Size Calculation software. The 
calculation of sample size was as follows: 
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α   Level of significant = 0.05 
Power 0.8 
Pο  0.47(Proportion of LDL achievers among male  patients)(42) 
P1  0.67 (expected  proportion of LDL nonachievers among male patients)  
m = 1   
 
The sample size shown by the PS Software= 95, Therefore the final number of sample requirred is 
95(1+1) =190. After considering the non-respond rate of 30%, the number of patients needed in 
this study was 247. 
Numerical variables 
The calculation of the sample size was as follows:  
α = 0.05 
Power =0.8 
σ =  9.2(standard deviation of mean age in LDL-C nonachievers)(42)  
δ = 5(expected detectable difference mean age of LDL-C  achievers and LDL-C 
nonachievers) 
m 1 
Sample size by shown by PS Software= 54, Therefore the final number of sample requirred is 
54(1+1) =108. After considering the non-respond rate of 30%, the number of patients needed in 
this study was 140. 
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Table 4.1 Sample size culculation for categorical variables 
Variables P0 P1 Minimum sample 
size(n) 
n+30% 
 
 
Gender(42)  
 
0.47 
 
0.67 
 
190 
 
247 
Adherence group(42) 0.59 0.39 194 252 
 
 
Table 4.2 Sample size culculation for numerical variables 
Variables σ δ Minimum sample 
size(n) 
n+30%  
Age 9.2 5 108 140 
BMI 3.6 2 104 135 
SBP 19.6 10 122 158 
DBP 12 8 190 247 
 
The biggest sample size belongs to objective 3 which was 252. In this study,  the sample size 
of 252 was used. 
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4.4 Research tools 
The research tools consisted of: 
1)  Case report Form. This section was filled up by interviewer. 
a. Socio demographic data consists of information regarding age; sex; race; marital status; 
smoking status; occupation; income and education level. 
b. Clinical data information including medications (number of medications and type of 
statin), investigations result (lipid profile and HbA1c) and examinations (weight, 
height and blood pressure).  
2) Self administered questionnaires. This section was filled up by study subjects. 
a. Patient‘s treatment data which includes information about the duration anticholesterol 
medication consumption, knowledge and side effects of anticholesterol medication 
consumed. 
b. Medication adherence questionnaire: Medication Compliance Questionnaire(MCQ) was 
used in this study. It was developed by Hassan et al in 2006 to assess adherence 
towards antihypertensive medication(45). It is comprised of  a set of 10 questions 
which consists of  2 domains: a drug taking behaviour domain comprising 7 items and 
a drug stopping behaviour domain comprising 3 items . The internal consistency 
realibilities (cronbach alpha) were 0.67 and 0.84 and test-retest single measure 
intraclass correlation coefficient were 0.78 and 0.83. The scores are calculated using 
the  Likert scale ranging from 1 to 5 with 1 indicating ‗never‘ and 5 indicating ‗very 
frequent‘. All negatively worded scores were reversed and all scores were converted to 
0 to 100 score. Patient with good compliance or adherence with a score of   ≥ 75% 
correspond with ‗ frequently‘ and ‗very frequently‘ for all item in the questionnaire. 
